

Accepted Manuscript

Pharmacokinetics and safety of a single dose of the novel LAMA/LABA fixed-dose combination of glycopyrronium/formoterol fumarate dihydrate metered dose inhaler, formulated using co-suspension delivery technology, in Japanese healthy subjects

Colin Reisner, Joel Miller, Paolo DePetrillo, Andrea Maes, Shahid Siddiqui, Ubaldo J. Martin

PII: S1094-5539(18)30080-4

DOI: [10.1016/j.pupt.2018.09.005](https://doi.org/10.1016/j.pupt.2018.09.005)

Reference: YPUPT 1750

To appear in: *Pulmonary Pharmacology & Therapeutics*


Received Date: 27 March 2018

Revised Date: 23 August 2018

Accepted Date: 10 September 2018

Please cite this article as: Reisner C, Miller J, DePetrillo P, Maes A, Siddiqui S, Martin UJ, Pharmacokinetics and safety of a single dose of the novel LAMA/LABA fixed-dose combination of glycopyrronium/formoterol fumarate dihydrate metered dose inhaler, formulated using co-suspension delivery technology, in Japanese healthy subjects, *Pulmonary Pharmacology & Therapeutics* (2018), doi: <https://doi.org/10.1016/j.pupt.2018.09.005>.

This is a PDF file of an unedited manuscript that has been accepted for publication. As a service to our customers we are providing this early version of the manuscript. The manuscript will undergo copyediting, typesetting, and review of the resulting proof before it is published in its final form. Please note that during the production process errors may be discovered which could affect the content, and all legal disclaimers that apply to the journal pertain.



**Pharmacokinetics and safety of a single dose of the novel LAMA/LABA
fixed-dose combination of glycopyrronium/formoterol fumarate dihydrate
metered dose inhaler, formulated using co-suspension delivery technology,
in Japanese healthy subjects**

Colin Reisner^{a,b,*}, Joel Miller^c, Paolo DePetrillo^d, Andrea Maes^a, Shahid Siddiqui^b,
Ubaldo J. Martin^b

^a*Pearl – a member of the AstraZeneca Group, Morristown, NJ, USA*

^b*AstraZeneca, Gaithersburg, MD, USA*

^c*Everest Clinical Research, Little Falls, NJ, USA*

^d*Pharmaron, Baltimore, MD, USA*

*Corresponding author. Pearl – a member of the AstraZeneca Group, 280 Headquarters Plaza, East Tower, 2nd Floor, Morristown, NJ 07960, USA.

Email address: Colin.Reisner@astrazeneca.com (C Reisner)

Phone number: 001 973 975 0321

Dr Joel Miller, Everest Clinical Research, 150 Clove Road, Suite 502, Little Falls, New Jersey 07424, USA. Email: joel.miller@ecrscorp.com

Dr Paolo DePetrillo, Pharmaron, 800 W. Baltimore St., Baltimore, MD 21201, USA. Email: paolo.depitrillo@pharmaron-us.com

Dr Andrea Maes, Pearl – a member of the AstraZeneca Group, 280 Headquarters Plaza, East Tower, 2nd Floor, Morristown, NJ 07960, USA. Email: Andrea.Maes@astrazeneca.com

Download English Version:

<https://daneshyari.com/en/article/10158576>

Download Persian Version:

<https://daneshyari.com/article/10158576>

[Daneshyari.com](https://daneshyari.com)